Showing 10,551 - 10,560 of 636,227
During the last several years, government spending on drugs used to treat schizophrenia and other psychotic illnesses has increased at more than 30% per year, with the $3 billion in 2001 Medicaid expenditures exceeding spending in any other therapeutic category. This growth has been primarily...
Persistent link: https://www.econbiz.de/10012469072
Rapid technological progress has been a defining feature of the medical sector over the last century, yet we know little about the determinants of the development of these new technologies. This paper examines whether and to what extent the demand-side incentives embodied in health policy affect...
Persistent link: https://www.econbiz.de/10012469243
relative magnitudes of the two sources of competition in limiting innovative returns in the U.S. pharmaceuticals market. In …
Persistent link: https://www.econbiz.de/10012469403
We analyze the effects on consumers of an extreme policy experiment -- Napsterizing' pharmaceuticals -- whereby all … associated with greater access to the current stock of pharmaceuticals, future consumers will be harmed by reducing the flow of … new pharmaceuticals to the market. Our estimates of the consumer surpluses at stake are based on the stylized facts …
Persistent link: https://www.econbiz.de/10012469480
individuals are more likely to adopt new medical technologies. We investigate this theory by asking whether more educated people …
Persistent link: https://www.econbiz.de/10012469525
We hypothesize that pharmaceutical-embodied technical progress increases per capita output via its effect on labor supply (the employment rate and hours worked per employed person). We examine the effect of changes in both the average quantity and average vintage (FDA approval year) of drugs...
Persistent link: https://www.econbiz.de/10012469570
We update and extend our previous study of the effect of drug age -- years since FDA approval -- on total medical expenditure, in several respects. The estimates indicate that, in the entire population, a reduction in the age of drugs utilized reduces non-drug expenditure 7.2 times as much as it...
Persistent link: https://www.econbiz.de/10012469718
Between 1960 and 1997, life expectancy at birth of Americans increased approximately 10% - from 69.7 to 76.5 years - and it has been estimated that the value of life extension during this period nearly equaled the gains in tangible consumption. We investigate whether an aggregate health...
Persistent link: https://www.econbiz.de/10012469960
I investigate the effect of large increases in the number of drugs available to treat rare diseases and HIV on mortality associated with them. Mortality from both diseases declined dramatically following increases in drug approvals. Before the Orphan Drug Act went into effect (between 1979 and...
Persistent link: https://www.econbiz.de/10012470038
This paper uses detailed data on retail pharmacy transactions to make inferences about the nature and intensity of consumer search for prescription drugs. Prescription prices exhibit patterns that should, in principle, induce search: in particular, prices vary widely across stores, and stores'...
Persistent link: https://www.econbiz.de/10012470170